Patients with stage II , III , or IVA esophageal cancer were randomly allocated to either 2 cycles of ICT ( oxaliplatin 130 mg/m ( 2 ) on day 1 and S1 at 40 mg/m ( 2 ) twice daily on days 1-14 , every 3 weeks ) followed by concurrent chemoradiotherapy ( CCRT ) ( 46 Gy , 2 Gy/d with oxaliplatin 130 mg/m ( 2 ) on days 1 and 21 and S1 30 mg/m ( 2 ) twice daily , 5 days per week during radiation therapy ) and esophagectomy ( arm A ) , or the same CCRT followed by esophagectomy without ICT ( arm B ) .